research PC-SPES Studies Promising, But Manufacturer Shuts Down
Promising cancer treatments were found, but the manufacturer closed.
Search
for
Sort by
Research
120-150 / 1000+ results
research Mirtazapine-induced Gynecomastia: An Unknown Side Effect?
Mirtazapine can cause male breast enlargement.
research A woman with iatrogenic androgenetic alopecia responding to finasteride
EF and PXE not closely related.
research Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data
Tralokinumab for atopic dermatitis may cause side effects like dizziness, headache, nausea, hair loss, and acne.
research 724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata
Rezpegaldesleukin shows promise for treating severe alopecia areata.
research 42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events
Ixekizumab is safe for long-term use with low rates of major heart-related events.
research Non-scarring Alopecia in Pemphigus Foliaceus
Rituximab treatment led to complete hair regrowth and improved skin in a woman with pemphigus foliaceus.
research Alopécie frontale fibrosante : étude prospective de 20 cas
The study found that a specific type of hair loss is increasingly common in premenopausal women and can be effectively diagnosed and treated with various medications.
research A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
research Frontal fibrosing alopecia: A multicenter review of 355 patients
Most patients with frontal fibrosing alopecia are postmenopausal women, and treatments like finasteride and dutasteride can improve or stabilize the condition.
research Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
research Ixekizumab Improved Refractory Erythrodermic Psoriasis with Comorbid Diffuse Alopecia: A Case Report with 52-Week Follow-Up
Ixekizumab effectively treated severe psoriasis and hair loss in a patient.
research 307 Dermatologic toxicities associated with chronic gamma-secretase inhibitor treatment for desmoid tumor
Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
research (369) Physician Insights into the Safety of Flibanserin for the Treatment of Sexual Dysfunction in Men
Flibanserin shows promise for treating male sexual dysfunction but has side effects like insomnia and fatigue.
research Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839
ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
research Treatment of postmenopausal frontal fibrosing alopecia with oral dutasteride
Oral dutasteride can potentially treat frontal fibrosing alopecia in postmenopausal women, with some patients showing disease arrest and hair regrowth.
research Old drug new indication: Tofacitinib for a new crop of hair?
Tofacitinib might be used to treat hair loss.
research ¿Novedad o prudencia? El delicado equilibrio en la actualización farmacológica
New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
research Frontal Fibrosing Alopecia: A Retrospective Analysis of 72 Patients from a German Academic Center
Combination therapy with steroids and pimecrolimus improved or stabilized hair loss in most patients with Frontal Fibrosing Alopecia, who also had a high rate of hypothyroidism.
research 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
research The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
research Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management
The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
research Association between finasteride with subjective memory deficits: a study from the NHANES and FAERS databases
Finasteride use is linked to a higher risk of memory problems.
research 1113 Targeting anti-inflammatory immunonanocarriers to human and murine neutrophils via Ly6 antigen for psoriasiform dermatitis alleviation
The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.
research Effect of Fexofenadine as an Adjunct to DPCP in Non-Atopic Patients with Alopecia Areata: A Randomized Clinical Trial
Fexofenadine reduces discomfort but doesn't significantly improve hair regrowth in Alopecia Areata treatment.
research Enhanced Insights into Frontal Fibrosing Alopecia: Advancements in Pathogenesis Understanding and Management Strategies
Frontal Fibrosing Alopecia needs better diagnostics and treatments, with dutasteride showing promise.
research BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer
Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
research Frontal Fibrosing Alopecia: Successfully Treated with Methotrexate or Just the Natural Disease Progression?
Methotrexate may help stabilize frontal fibrosing alopecia.
research The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B‐rapidly accelerated fibrosarcoma‐mutated advanced melanoma
The combination of encorafenib and binimetinib caused few skin issues.
research Assessing finasteride-associated sexual dysfunction using the FAERS database
Finasteride and dutasteride increase sexual dysfunction reports.